Allison Dorval Sells 3,350 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) Stock

Verve Therapeutics, Inc. (NASDAQ:VERV) CFO Allison Dorval sold 3,350 shares of the firm’s stock in a transaction that occurred on Wednesday, April 2nd. The shares were sold at an average price of $4.15, for a total value of $13,902.50. Following the completion of the sale, the chief financial officer now directly owns 13,280 shares of the company’s stock, valued at $55,112. The trade was a 20.14 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Verve Therapeutics Stock Down 6.0 %

VERV opened at $3.62 on Friday. The company has a market capitalization of $321.44 million, a P/E ratio of -1.47 and a beta of 1.77. Verve Therapeutics, Inc. has a 52 week low of $3.46 and a 52 week high of $9.31. The stock’s fifty day moving average is $6.61 and its two-hundred day moving average is $6.02.

Verve Therapeutics (NASDAQ:VERV) last announced its earnings results on Thursday, February 27th. The company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.72) by $0.14. The firm had revenue of $13.08 million for the quarter, compared to the consensus estimate of $3.94 million. Verve Therapeutics had a negative return on equity of 35.23% and a negative net margin of 807.65%. Equities analysts anticipate that Verve Therapeutics, Inc. will post -2.49 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several analysts recently weighed in on VERV shares. William Blair restated an “outperform” rating on shares of Verve Therapeutics in a report on Friday, February 21st. HC Wainwright reissued a “buy” rating and issued a $15.00 price objective on shares of Verve Therapeutics in a research report on Tuesday, March 25th. Royal Bank of Canada dropped their target price on Verve Therapeutics from $17.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, March 4th. Finally, Guggenheim reaffirmed a “buy” rating on shares of Verve Therapeutics in a research note on Tuesday, March 25th. Five investment analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $20.67.

Institutional Trading of Verve Therapeutics

Large investors have recently added to or reduced their stakes in the company. BVF Inc. IL lifted its holdings in shares of Verve Therapeutics by 962.2% during the fourth quarter. BVF Inc. IL now owns 6,904,050 shares of the company’s stock worth $38,939,000 after purchasing an additional 6,254,050 shares during the period. State Street Corp lifted its stake in Verve Therapeutics by 27.0% during the 3rd quarter. State Street Corp now owns 4,253,217 shares of the company’s stock valued at $20,586,000 after acquiring an additional 903,809 shares during the period. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Verve Therapeutics by 57.4% in the 4th quarter. Schonfeld Strategic Advisors LLC now owns 3,789,379 shares of the company’s stock valued at $21,372,000 after acquiring an additional 1,382,176 shares during the last quarter. Jacobs Levy Equity Management Inc. increased its stake in shares of Verve Therapeutics by 18.5% in the fourth quarter. Jacobs Levy Equity Management Inc. now owns 1,848,071 shares of the company’s stock worth $10,423,000 after acquiring an additional 288,678 shares during the period. Finally, Geode Capital Management LLC raised its holdings in shares of Verve Therapeutics by 1.6% during the fourth quarter. Geode Capital Management LLC now owns 1,625,780 shares of the company’s stock worth $9,172,000 after purchasing an additional 25,093 shares during the last quarter. Hedge funds and other institutional investors own 97.11% of the company’s stock.

Verve Therapeutics Company Profile

Verve Therapeutics, Inc, a clinical stage genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases in the United States. The company's lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver; and VERVE-102, a product candidate that targets the PCSK9 gene for the treatment of HeFH.